Coherus Oncology (CHRS) Minority Interest (2016 - 2018)
Historic Minority Interest for Coherus Oncology (CHRS) over the last 5 years, with Q2 2018 value amounting to -$1.3 million.
- Coherus Oncology's Minority Interest fell 452.07% to -$1.3 million in Q2 2018 from the same period last year, while for Jun 2018 it was -$1.3 million, marking a year-over-year decrease of 452.07%. This contributed to the annual value of -$1.3 million for FY2017, which is 988.92% down from last year.
- According to the latest figures from Q2 2018, Coherus Oncology's Minority Interest is -$1.3 million, which was down 452.07% from -$1.3 million recorded in Q1 2018.
- Coherus Oncology's 5-year Minority Interest high stood at -$44000.0 for Q4 2014, and its period low was -$1.3 million during Q2 2018.
- For the 5-year period, Coherus Oncology's Minority Interest averaged around -$872250.0, with its median value being -$1.1 million (2016).
- Per our database at Business Quant, Coherus Oncology's Minority Interest crashed by 154090.91% in 2015 and then crashed by 452.07% in 2018.
- Coherus Oncology's Minority Interest (Quarter) stood at -$44000.0 in 2014, then crashed by 1540.91% to -$722000.0 in 2015, then tumbled by 62.47% to -$1.2 million in 2016, then decreased by 9.89% to -$1.3 million in 2017, then dropped by 4.03% to -$1.3 million in 2018.
- Its Minority Interest stands at -$1.3 million for Q2 2018, versus -$1.3 million for Q1 2018 and -$1.3 million for Q4 2017.